Table 2 Proportion of patients with 1-year TRA and associated characteristics among 789 eligible participants.
From: Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer
Characteristic | TRA at 1 year | Univariable analysis | p-value | Multivariable analysis | p-value |
|---|---|---|---|---|---|
n (%) | OR (95% CI) | OR (95% CI) | |||
Total cohort | 286/789 (36.2%) | ||||
Age at diagnosis (years) | |||||
≤30 | 23/109 (21.1%) | 0.40 (0.24–0.64) | <0.01 | 0.29 (0.17–0.48) | <0.001 |
31–35 | 76/216 (35.2%) | 0.80 (0.57–1.12) | 0.20 | 0.66 (0.46–0.94) | 0.024 |
36–40 | 187/464 (40.3%) | Ref | Ref | Ref | Ref |
BMI | |||||
<18.5 | 12/38 (31.6%) | 0.72 (0.34–1.43) | 0.36 | 0.90 (41–1.90) | 0.792 |
18.5–24.9 | 186/476 (39.1%) | Ref | Ref | Ref | Ref |
≥25 | 73/241 (30.3%) | 0.68 (0.49–0.94) | 0.02 | 0.61 (0.42–0.86) | 0.006 |
Missing | 15/34 (44.1%) | ||||
Race | |||||
Non-White | 43/118 (36.4%) | 1.00 (0.67–1.51) | 0.96 | ||
White | 243/671 (36.2%) | Ref | Ref | ||
Smoking | |||||
Active/former | 83/255 (32.6%) | 0.79 (0.58–1.09) | 0.16 | 0.83 (0.59–1.17) | 0.296 |
Never | 186/492 (37.8%) | Ref | Ref | Ref | |
Missing | 17/42 (40.5%) | ||||
Tamoxifen use at 1 year | |||||
No | 89/296 (30.1%) | Ref | Ref | Ref | Ref |
Yes | 182/459 (39.7%) | 1.53 (1.12–2.09) | <0.01 | 1.55 (1.12–2.16) | 0.009 |
Missing | 15/34 (44.1%) | ||||
Chemotherapy | |||||
Yes | 258/592 (43.6%) | 4.66 (3.07–7.31) | <0.01 | 5.57 (3.62–8.86) | <0.001 |
No | 28/197 (14.2%) | Ref | Ref | Ref | Ref |
